Educational Videos

Release date: 29 July 2020 Cytokine Signalling Inhibitors: Update from EULAR 2020
Developed by CESAS Medical, under the auspices of the University of Glasgow. This activity is supported by unrestricted educational grants from Lilly, AbbVie, Gilead/Galapagos and Pfizer

Estimated time to complete activity: 1 hour
Compatible with all modern internet browsers and mobile devices

EDUCATIONAL OBJECTIVES
After completing this activity, the learner will:

• Understand the mode of action of JAK inhibitors

• Be up to date on the safety and efficacy of JAK Inhibitors in RA, JIA and PsA

• Understand the clinical predictors and comparative effectiveness of JAK inhibitors in patients with RA

TARGET AUDIENCE
This activity is designed for qualified rheumatologists of all levels of seniority, and other healthcare professionals involved in treating patients with inflammatory disease.

PROGRAMME OVERVIEW
EULAR 2020 presented new scientific and clinical information on cytokine signalling science that will shape the rheumatology treatment landscape. Data presented included those relating to JAK inhibitors in clinical practice and in development across RA, JIA and PsA.

In this activity, Cytokine Signalling Inhibitors: Update from EULAR 2020, international experts review and discuss key abstracts and data from EULAR 2020 specifically relating to the mode of action, safety and efficacy, and comparative effectiveness of JAK inhibitors.

This course, Cytokine Signalling Inhibitors: Update from EULAR 2020, outlines recent developments in cytokine signalling science in RA, JIA and PsA, and discusses the importance of these new data for clinical practice. The learner’s understanding of the information presented will be assessed following each of the course modules.

INSTRUCTIONS FOR PARTICIPATION
Participants must 1) read the activity information; 2) study the educational activity; 3) successfully complete the post-module assessments with a score of 80% or better; 4) and complete the evaluation form. Upon completion of the full activity, your certificate will be made available to download and print.

DISCLOSURE OF CONFLICTS OF INTEREST
CESAS Medical requires faculty, presenters, planners, managers, writers, and any other individuals who are in a position to influence the content of this activity to disclose any real and/or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly reviewed and resolved according to CESAS Medical policy.

ACCREDITATION STATEMENT
The e-learning activity, Cytokine Signalling Inhibitors: Update from EULAR 2020, organised by CESAS Medical, under the auspices of the University of Glasgow, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The e-learning activity, Cytokine Signalling Inhibitors: Update from EULAR 2020, organised by CESAS Medical, under the auspices of the University of Glasgow, is awarded 1 European CME credits (ECMECs).

Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS-EACCME website have formally been accredited. Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.